Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with...

Area of Science:

• Immunology
• Infectious Diseases
• Hematology

Background:

• Limited understanding of the interplay between neutralizing antibodies, cytokines, and treatments like convalescent plasma therapy in COVID-19.
• Need for clarity on the immunological response to convalescent plasma in patients with moderate-to-severe pneumonia.

Purpose of the Study:

• To investigate the connection between immunological response and convalescent plasma therapy efficacy in COVID-19 patients.
• To analyze antibody levels, cytokine profiles, and clinical outcomes following transfusion.

Main Methods:

• Retrospective analysis of 49 COVID-19 patients (age 35-57) with moderate-to-severe pneumonia.
• Clinical assessments including antibody titers (anti-nucleocapsid, anti-spike, neutralizing), cytokine levels (IFN-β, IL-6, IL-10, IFN-α), and biochemical markers (CRP, D-dimer) before and after transfusion.
• Evaluation of patient discharge and mortality rates.

Main Results:

• Significant increase in anti-nucleocapsid, anti-spike, and neutralizing antibodies post-transfusion (days 3, 7, 14).
• Significant variations in serum CRP and D-dimer levels across sampling points.
• Convalescent plasma therapy demonstrated immunoregulatory effects on cytokine parameters, with significant changes in IFN-β, IL-6, IL-10, and IFN-α.

Conclusions:

• Convalescent plasma therapy is associated with enhanced antibody levels and immunomodulation in COVID-19 patients.
• Monitoring cytokine signatures alongside clinical parameters can help identify cytokine storms and guide anti-cytokine treatment indications.
• High discharge rate (98%) suggests potential efficacy of convalescent plasma in this patient cohort.